https://www.pharmaradar360.com/article/high-costs-taxes-keep-nigeria-dependent-on-imported-drug-inputs-psn-de7b24572476461cPharmaRadar360en2026-09-27T15:33:40.000ZHigh Costs,Taxes Keep Nigeria Dependent On Imported Drug Inputs—PSNhttps://www.pharmaradar360.com/article/form-144-legend-biotech-corp-for-27-september-by-investing-com-325ce041d79d35b0PharmaRadar360en2026-09-27T13:48:09.000ZForm 144 Legend Biotech Corp For: 27 September By Investing.comhttps://www.pharmaradar360.com/article/3-indian-growth-stocks-with-revenue-growth-up-to-27-43fee28c579d870fPharmaRadar360en2026-09-27T13:38:03.000Z3 Indian Growth Stocks With Revenue Growth Up To 27%https://www.pharmaradar360.com/article/fake-anti-rabies-vaccines-case-fir-lodged-against-two-kanpur-pharmaceutical-agen-3d8f5c7c69891897PharmaRadar360en2026-09-27T12:56:33.000ZFake Anti-Rabies Vaccines Case: FIR Lodged Against Two Kanpur Pharmaceutical Agencieshttps://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-xbi-stock-price-news-quote-history-d4dae5114aa6fc80PharmaRadar360en2026-09-27T12:55:33.000ZState Street SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & Historyhttps://www.pharmaradar360.com/article/innovation-is-driving-a-new-bull-market-in-biotech-16-ways-to-play-it-from-our-r-fe116bb5058c4328PharmaRadar360en2026-09-27T12:46:00.000ZInnovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.https://www.pharmaradar360.com/article/china-s-advances-in-pharma-create-new-opportunities-for-pakistan-f139216a76bfd03ePharmaRadar360en2026-09-27T12:45:00.000ZChina’s advances in pharma create new opportunities for Pakistanhttps://www.pharmaradar360.com/article/fda-approves-new-parkinson-s-drug-that-targets-dopamine-receptors-all-about-tava-783438ee9fbeb0ffPharmaRadar360en2026-09-27T12:30:00.000ZFDA Approves New Parkinson’s Drug That Targets Dopamine Receptors: All About Tavapadonhttps://www.pharmaradar360.com/article/two-chinese-ipos-open-for-subscription-monday-guizhou-s-southern-dairy-at-14-21-99d23c8c332cc0f6PharmaRadar360en2026-09-27T12:25:00.000ZTwo Chinese IPOs Open for Subscription Monday: Guizhou's Southern Dairy at 14.21 Yuan, Lianya Pharmaceutical Seen as High Allotment-Rate Playhttps://www.pharmaradar360.com/article/iberdomide-doubles-mrd-negative-cr-rate-in-phase-3-excaliber-rrmm-trial-ec3c4892a0321716PharmaRadar360en2026-09-27T12:05:26.000ZIberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trialhttps://www.pharmaradar360.com/article/mount-kenya-university-to-unveil-new-pharmacy-courses-fa16b2c3a84651c3PharmaRadar360en2026-09-27T12:03:29.000ZMount Kenya University to unveil new pharmacy courseshttps://www.pharmaradar360.com/article/form-4-teva-pharmaceutical-industries-ltd-for-27-september-by-investing-com-42d0210e01173842PharmaRadar360en2026-09-27T11:32:00.000ZForm 4 TEVA PHARMACEUTICAL INDUSTRIES LTD For: 27 September By Investing.comhttps://www.pharmaradar360.com/article/tributes-paid-after-death-of-powys-pharmaceutical-pioneer-sir-roger-jones-a317651e7abf0b33PharmaRadar360en2026-09-27T11:00:00.000ZTributes paid after death of Powys pharmaceutical pioneer Sir Roger Joneshttps://www.pharmaradar360.com/article/the-gray-zone-between-wellness-and-medical-practice-as-experts-urge-strict-overs-d610109d330fb461PharmaRadar360en2026-09-27T10:55:03.000ZThe gray zone between wellness and medical practice as experts urge strict oversight in Cyprushttps://www.pharmaradar360.com/article/uzbekistan-eyes-investment-in-afghanistan-s-pharmaceutical-sector-3b860121a6a54363PharmaRadar360en2026-09-27T10:52:38.000ZUzbekistan Eyes Investment in Afghanistan’s Pharmaceutical Sectorhttps://www.pharmaradar360.com/article/vogue-world-in-milan-faces-backlash-over-pharmaceutical-sponsorship-amidst-contr-6a1cf175a9a3178dPharmaRadar360en2026-09-27T10:46:53.000ZVogue World in Milan Faces Backlash Over Pharmaceutical Sponsorship Amidst Controversy on Body Imagehttps://www.pharmaradar360.com/article/team-behind-york-biotech-campus-incredibly-proud-as-site-celebrates-its-30th-ann-77c25d393410c9d0PharmaRadar360en2026-09-27T10:45:00.000ZTeam behind York Biotech Campus ‘incredibly proud’ as site celebrates its 30th anniversaryhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hunan-er-kang-pharmaceutical-co-ltd-class-afdb2e2893faee3fPharmaRadar360en2026-09-27T10:32:18.000ZEnterprise value to EBITDA forward of Hunan Er-Kang Pharmaceutical Co., Ltd. Class A – SZSE:300267https://www.pharmaradar360.com/article/spdr-s-p-biotech-etf-xbi-stock-price-news-quote-and-history-c496072a78141080PharmaRadar360en2026-09-27T10:29:26.000ZSPDR S&P Biotech ETF (XBI) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/fda-nominee-says-vaccines-are-safe-despite-trump-efforts-to-overhaul-childhood-s-a7323e2ace37ae61PharmaRadar360en2026-09-27T10:21:07.000ZFDA nominee says vaccines are safe despite Trump efforts to overhaul childhood shotshttps://www.pharmaradar360.com/article/china-s-advances-in-pharma-create-new-opportunities-for-pakistan-71e3f98bc5800567PharmaRadar360en2026-09-27T10:00:54.000ZChina’s advances in pharma create new opportunities for Pakistanhttps://www.pharmaradar360.com/article/food-safety-laws-exist-but-compliance-remains-a-challenge-maha-fda-76e341dee8887699PharmaRadar360en2026-09-27T09:56:15.000ZFood safety laws exist, but compliance remains a challenge: Maha FDAhttps://www.pharmaradar360.com/article/stakeholders-want-uganda-s-pharmaceutical-import-dependence-to-reduce-650923b2974e4cf3PharmaRadar360en2026-09-27T09:44:19.000ZStakeholders want Uganda’s pharmaceutical import dependence to reducehttps://www.pharmaradar360.com/article/obituary-kim-dong-yeon-former-chairman-of-bukwang-pharmaceutical-02f3b555b012fe12PharmaRadar360en2026-09-27T09:32:00.000ZObituary: Kim Dong-yeon, former chairman of Bukwang Pharmaceuticalhttps://www.pharmaradar360.com/article/four-aim-miners-and-a-biotech-move-from-promise-to-proof-cd427cb1c1513f37PharmaRadar360en2026-09-27T09:31:57.000ZFour AIM Miners And A Biotech Move From Promise To Proofhttps://www.pharmaradar360.com/article/3-numbers-from-viking-therapeutics-weight-loss-drug-trial-that-have-wall-street-25b33acd00c34ed7PharmaRadar360en2026-09-27T09:15:00.000Z3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzinghttps://www.pharmaradar360.com/article/iran-runs-short-of-critical-medicines-as-us-blockade-disrupts-supplies-678826ab8c02692bPharmaRadar360en2026-09-27T08:35:14.000ZIran runs short of critical medicines as US blockade disrupts supplieshttps://www.pharmaradar360.com/article/pakistani-chinese-companies-sign-agreement-to-expand-industrial-and-commercial-l-ef253c1ab605a84fPharmaRadar360en2026-09-27T08:31:13.000ZPakistani, Chinese companies sign agreement to expand industrial and commercial linkageshttps://www.pharmaradar360.com/article/silkway-impex-advances-partnerships-with-chinese-companies-in-infrastructure-pha-84102be3b7efbf7fPharmaRadar360en2026-09-27T08:01:25.000ZSilkway Impex advances partnerships with Chinese companies in infrastructure, pharma, steelhttps://www.pharmaradar360.com/article/what-trump-s-most-favoured-nation-drug-pricing-policy-might-mean-for-canadians-90961d18c1e47354PharmaRadar360en2026-09-27T08:00:00.000ZWhat Trump's 'most favoured nation' drug pricing policy might mean for Canadianshttps://www.pharmaradar360.com/article/pune-fda-seizes-28-53-lakh-worth-of-food-stock-7-licences-suspended-banned-tobac-097befb17b72fc31PharmaRadar360en2026-09-27T07:01:12.000ZPune FDA Seizes ₹28.53 Lakh Worth Of Food Stock; 7 Licences Suspended, Banned Tobacco Worth ₹1.98 Lakhhttps://www.pharmaradar360.com/article/kodiak-sciences-to-report-daybreak-phase-3-results-for-zenkuda-and-ksi-501-73668da8d47bf721PharmaRadar360en2026-09-27T06:38:50.000ZKodiak Sciences to Report DAYBREAK Phase 3 Results for Zenkuda and KSI-501https://www.pharmaradar360.com/article/headlands-research-joins-scrs-global-impact-partner-program-06bae840ca1834b7PharmaRadar360en2026-09-27T06:38:50.000ZHeadlands Research Joins SCRS Global Impact Partner Programhttps://www.pharmaradar360.com/article/5-indian-companies-earning-the-highest-revenue-of-up-to-80-6-from-the-us-20677379732a8072PharmaRadar360en2026-09-27T06:30:38.000Z5 Indian Companies Earning the Highest Revenue of up to 80.6% From the UShttps://www.pharmaradar360.com/article/avianca-cargo-obtains-gdp-pharma-certification-and-strengthens-its-european-netw-486c5e5912a03f41PharmaRadar360en2026-09-27T05:59:11.000ZAvianca Cargo Obtains GDP Pharma Certification and Strengthens Its European Networkhttps://www.pharmaradar360.com/article/sellas-life-sciences-draws-significant-retail-buzz-as-traders-eye-regal-phase-3-8573551db14a7498PharmaRadar360en2026-09-27T05:58:18.000ZSellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15%https://www.pharmaradar360.com/article/symbiotec-pharmalab-with-57-market-share-across-key-steroid-apis-why-is-it-betti-aaf4ef502ab3b000PharmaRadar360en2026-09-27T04:31:37.000ZSymbiotec Pharmalab: With 57% Market Share Across Key Steroid APIs, Why Is It Betting Big on Insulin and Alternative Proteins?https://www.pharmaradar360.com/article/korea-manufacturing-optimism-broadens-as-chips-hit-record-five-sectors-top-100-c-a48838d30d421051PharmaRadar360en2026-09-27T04:30:00.000ZKorea manufacturing optimism broadens as chips hit record, five sectors top 100 - CHOSUNBIZhttps://www.pharmaradar360.com/article/the-sahrawi-pharmaceutical-lab-battling-against-sand-and-shortages-we-are-a-rose-f0e7205310179a0fPharmaRadar360en2026-09-27T04:00:00.000ZThe Sahrawi pharmaceutical lab battling against sand and shortages: ‘We are a rose in the desert’https://www.pharmaradar360.com/article/t-rowe-price-s-new-active-biotech-and-small-cap-etfs-might-change-the-case-for-i-c51aae51eae3a9daPharmaRadar360en2026-09-27T03:16:00.000ZT. Rowe Price’s New Active Biotech and Small-Cap ETFs Might Change The Case For Investing In TROWhttps://www.pharmaradar360.com/article/hanall-biopharma-halts-lupus-drug-trial-pivots-to-rheumatoid-arthritis-dce1a4ebe83c3499PharmaRadar360en2026-09-27T02:35:00.000ZHanAll Biopharma Halts Lupus Drug Trial, Pivots to Rheumatoid Arthritishttps://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581PharmaRadar360en2026-09-27T01:44:48.000ZDFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?https://www.pharmaradar360.com/article/p-cab-makers-turn-to-diabetes-drugs-for-next-growth-engine-da931bb9ed826602PharmaRadar360en2026-09-27T01:00:05.000ZP-CAB Makers Turn to Diabetes Drugs for Next Growth Enginehttps://www.pharmaradar360.com/article/uaeu-emirates-biotech-launch-uae-s-first-organic-waste-valorization-pilot-plant-7776c6508fb95fe0PharmaRadar360en2026-09-27T00:56:55.000ZUAEU & Emirates Biotech launch UAE’s first organic-waste valorization pilot planthttps://www.pharmaradar360.com/article/hanall-biopharma-halts-lupus-bid-pivots-to-arthritis-as-china-setback-deepens-ch-f259b0b68cff907cPharmaRadar360en2026-09-27T00:56:00.000ZHanAll Biopharma halts lupus bid, pivots to arthritis as China setback deepens - CHOSUNBIZhttps://www.pharmaradar360.com/article/livzon-pharmaceutical-shareholders-approve-egm-resolution-clearing-way-for-speci-9470590c6ee1a91dPharmaRadar360en2026-09-27T00:36:55.000ZLivzon Pharmaceutical Shareholders Approve EGM Resolution, Clearing Way for Special Dividendhttps://www.pharmaradar360.com/article/china-pledges-support-for-lanka-s-pharmaceutical-industry-f52fefd8663b323cPharmaRadar360en2026-09-27T00:36:47.000ZChina pledges support for Lanka’s pharmaceutical industryhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-0073cc37693089ccPharmaRadar360en2026-09-27T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-386ab1b37c72e551PharmaRadar360en2026-09-27T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-7dacac758d0d3053PharmaRadar360en2026-09-27T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-2740f768167242e3PharmaRadar360en2026-09-27T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-bc1f335f6e2b62d7PharmaRadar360en2026-09-27T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-730f005fc3219c9fPharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-06eb02a90ebbe6c4PharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-1e46567a43e33af6PharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-9f9fb01bc82c93ddPharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-66cdfdf01048dc1bPharmaRadar360en2026-09-27T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-ac6b0305dbd84a67PharmaRadar360en2026-09-27T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-ae54dab992c6feffPharmaRadar360en2026-09-27T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-833cdcaaea220bc8PharmaRadar360en2026-09-27T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-5db4a19242a7e626PharmaRadar360en2026-09-27T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/advanced-bioinformatics-tools-and-computational-strategies-for-drug-discovery-in-3afa13723fa96826PharmaRadar360en2026-09-27T00:00:00.000ZAdvanced Bioinformatics Tools and Computational Strategies for Drug Discovery in Biomedical Scienceshttps://www.pharmaradar360.com/article/development-and-characterization-of-gastroretentive-floating-tablets-of-domperid-0d241e2c57378bc1PharmaRadar360en2026-09-27T00:00:00.000ZDEVELOPMENT AND CHARACTERIZATION OF GASTRORETENTIVE FLOATING TABLETS OF DOMPERIDONE MALEATE AND FAMOTIDINE USING HYDROPHILIC POLYMER MATRIX.https://www.pharmaradar360.com/article/development-optimization-and-characterization-of-a-cow-ghee-based-doxorubicin-na-e0bc74f6a122120cPharmaRadar360en2026-09-27T00:00:00.000ZDEVELOPMENT, OPTIMIZATION AND CHARACTERIZATION OF A COW GHEE-BASED DOXORUBICIN NANOEMULSION FOR ENHANCED DRUG DELIVERY IN LUNG CANCERhttps://www.pharmaradar360.com/article/evaluating-pharmacovigilance-awareness-and-adverse-drug-reaction-reporting-among-2d11e592eb6eff42PharmaRadar360en2026-09-27T00:00:00.000ZEVALUATING PHARMACOVIGILANCE AWARENESS AND ADVERSE DRUG REACTION REPORTING AMONG UNDERGRADUATE HEALTHCARE STUDENTS FOLLOWING A STRUCTURED EDUCATIONAL PROGRAMMEhttps://www.pharmaradar360.com/article/transcorneal-permeation-enhancement-of-moxifloxacin-using-amino-acid-co-evaporat-cbd5fe512ea7d227PharmaRadar360en2026-09-27T00:00:00.000ZTRANSCORNEAL PERMEATION ENHANCEMENT OF MOXIFLOXACIN USING AMINO ACID CO-EVAPORATED SYSTEMShttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-drotaverine-hcl-and-mefenamic-acid-dispersible-tab-fe581e054794766aPharmaRadar360en2026-09-27T00:00:00.000ZFORMULATION AND EVALUATION OF DROTAVERINE HCL AND MEFENAMIC ACID DISPERSIBLE TABLETShttps://www.pharmaradar360.com/article/generative-artificial-intelligence-in-internal-medicine-applications-in-clinical-fbe85a0850aa8680PharmaRadar360en2026-09-27T00:00:00.000ZGenerative Artificial Intelligence in Internal Medicine: Applications in Clinical Reasoning, Differential Diagnosis, and Clinical Decision-Makinghttps://www.pharmaradar360.com/article/comprehensive-evaluation-of-tetralogy-of-fallot-superior-diagnostic-performance-028235781b32defaPharmaRadar360en2026-09-27T00:00:00.000ZComprehensive Evaluation of Tetralogy of Fallot: Superior Diagnostic Performance and Clinical Utility of MDCT Compared to Echocardiographyhttps://www.pharmaradar360.com/article/generative-ai-in-nursing-education-nurse-educators-perceptions-of-readiness-trus-87d4fec32d08b53aPharmaRadar360en2026-09-27T00:00:00.000ZGenerative AI in Nursing Education: Nurse Educators' Perceptions of Readiness, Trust, and Clinical Judgmenthttps://www.pharmaradar360.com/article/sex-stratified-sociodemographic-and-clinical-profile-of-maintenance-hemodialysis-1c74159e77415272PharmaRadar360en2026-09-27T00:00:00.000ZSex-Stratified Sociodemographic and Clinical Profile of Maintenance Hemodialysis Patients at a Remote Island Hospital in Bali: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/implementation-science-in-the-pharmaceutical-industry-why-we-know-which-innovati-c65a1a72e27ff304PharmaRadar360en2026-09-27T00:00:00.000ZImplementation Science in the Pharmaceutical Industry: Why we Know which Innovations Work but Still Cannot Implement Them - A Comparative Review of the United States, the European Union, and International Regulatory Contextshttps://www.pharmaradar360.com/article/digital-transformation-of-pharmaceutical-production-planning-in-saudi-arabia-usi-86037df7245c33c2PharmaRadar360en2026-09-27T00:00:00.000ZDigital Transformation of Pharmaceutical Production Planning in Saudi Arabia Using Integrated ERP Systemshttps://www.pharmaradar360.com/article/development-and-internal-validation-of-a-simplified-clinical-risk-score-for-syst-8adc1040d4a8bb90PharmaRadar360en2026-09-27T00:00:00.000ZDevelopment and Internal Validation of a Simplified Clinical Risk Score for Systemic Complications After Spine Surgery Using a Nationwide Japanese Registry: JOANR/JSSR-DBhttps://www.pharmaradar360.com/article/performance-evaluation-of-the-latest-general-purpose-large-language-models-in-me-76836b41c18c47f5PharmaRadar360en2026-09-27T00:00:00.000ZPerformance Evaluation of the Latest General-Purpose Large Language Models in Medical Reasoning and Clinical Screening Taskshttps://www.pharmaradar360.com/article/clinical-factors-associated-with-implant-removal-following-surgical-site-infecti-a92e90264ffdf7f7PharmaRadar360en2026-09-27T00:00:00.000ZClinical Factors Associated with Implant Removal Following Surgical Site Infection after Spinal Instrumentation Surgery for Lumbar Degenerative Diseasehttps://www.pharmaradar360.com/article/temporal-observations-of-multifidus-muscle-injury-and-degeneration-following-pos-a0c5621a3a0b98a7PharmaRadar360en2026-09-27T00:00:00.000ZTemporal Observations of Multifidus Muscle Injury and Degeneration Following Posterior Thoracolumbar Spine Surgery: A Clinical Histological Study over a Three-Year Time Periodhttps://www.pharmaradar360.com/article/relationship-between-postoperative-neuropathic-pain-and-clinical-scores-in-patie-623d4cd1eb315f38PharmaRadar360en2026-09-27T00:00:00.000ZRelationship between Postoperative Neuropathic Pain and Clinical Scores in Patients with Cervical Ossification of the Posterior Longitudinal Ligamenthttps://www.pharmaradar360.com/article/successful-limb-salvage-in-pediatric-nicolau-syndrome-following-intramuscular-be-b27aefb2659bd628PharmaRadar360en2026-09-27T00:00:00.000ZSuccessful Limb Salvage in Pediatric Nicolau Syndrome Following Intramuscular Benzathine Penicillin: A Case Reporthttps://www.pharmaradar360.com/article/serial-endoscopic-decompression-in-recurrent-sigmoid-volvulus-temporary-success-045557902e681105PharmaRadar360en2026-09-27T00:00:00.000ZSerial Endoscopic Decompression in Recurrent Sigmoid Volvulus: Temporary Success, Definitive Failurehttps://www.pharmaradar360.com/article/palmar-surprise-a-case-of-eccrine-poroma-with-review-of-literature-daaca22520e188d4PharmaRadar360en2026-09-27T00:00:00.000ZPalmar Surprise: A Case of Eccrine Poroma with Review of Literature.https://www.pharmaradar360.com/article/seizure-and-stroke-in-a-patient-with-down-syndrome-diagnosed-with-moyamoya-syndr-3a20d6c05b0b6babPharmaRadar360en2026-09-27T00:00:00.000ZSeizure and Stroke in a Patient with Down Syndrome Diagnosed with Moyamoya Syndrome: A Case Reporthttps://www.pharmaradar360.com/article/diagnostic-approach-and-therapeutic-interventions-in-ogilvie-syndrome-in-burn-pa-ac7dd47ea16c724bPharmaRadar360en2026-09-27T00:00:00.000ZDiagnostic Approach and Therapeutic Interventions in Ogilvie Syndrome in Burn Patients: A Report of Two Clinical Caseshttps://www.pharmaradar360.com/article/performance-optimization-focused-family-behavior-therapy-to-address-verbal-and-p-2b928b64016041f6PharmaRadar360en2026-09-27T00:00:00.000ZPerformance Optimization-Focused Family Behavior Therapy to Address Verbal and Physical Aggression in an Adolescent Diagnosed With Bipolar I Disorder: A Case Reporthttps://www.pharmaradar360.com/article/validation-of-the-estonian-versions-of-the-pediatric-symptom-checklist-17-youth-09184cc1a6ddd197PharmaRadar360en2026-09-27T00:00:00.000ZValidation of the Estonian Versions of the Pediatric Symptom Checklist-17 Youth Self-Report and Parent Reporthttps://www.pharmaradar360.com/article/from-institutional-experience-to-evidence-based-standards-for-psychiatric-app-pr-9511801540a64b68PharmaRadar360en2026-09-27T00:00:00.000ZFrom Institutional Experience to Evidence-Based Standards for Psychiatric APP Practicehttps://www.pharmaradar360.com/article/personalised-drug-recommender-systems-based-on-electronic-health-records-reprodu-84af5521dd6aed0fPharmaRadar360en2026-09-27T00:00:00.000ZPersonalised Drug Recommender Systems based on Electronic Health Records: Reproducibility and External Validityhttps://www.pharmaradar360.com/article/letter-to-the-editor-comment-on-the-impact-of-virtual-reality-with-relaxation-mu-794e3420b164396dPharmaRadar360en2026-09-27T00:00:00.000ZLetter to the Editor: Comment on “The Impact of Virtual Reality With Relaxation Music and Distraction Cards on Pain, Anxiety, and Satisfaction Levels of Women With an Intrauterine Device: A Randomized Controlled Trial”https://www.pharmaradar360.com/article/clinical-and-therapeutic-relevance-of-b7-h3-in-sarcomas-molecular-insights-from-71c941cdfd99a2a9PharmaRadar360en2026-09-27T00:00:00.000ZClinical and Therapeutic Relevance of B7-H3 in Sarcomas: Molecular Insights from a Systematic Reviewhttps://www.pharmaradar360.com/article/novel-cocrystal-inclusion-compound-of-bezafibrate-with-l-proline-preparation-cha-99ada7b94343909dPharmaRadar360en2026-09-27T00:00:00.000ZNovel cocrystal inclusion compound of bezafibrate with L-proline: preparation, characterization and in vitro/in vivo evaluationhttps://www.pharmaradar360.com/article/a-prospective-split-scar-randomized-controlled-trial-of-post-operative-silicone-fbe5117ebfc29a56PharmaRadar360en2026-09-27T00:00:00.000ZA prospective split-scar randomized controlled trial of post-operative silicone tape improves scar appearancehttps://www.pharmaradar360.com/article/osteosarcopenia-and-stability-of-fragility-pelvic-fractures-in-elderly-women-e4a493ef22b69abdPharmaRadar360en2026-09-27T00:00:00.000ZOsteosarcopenia and stability of fragility pelvic fractures in elderly womenhttps://www.pharmaradar360.com/article/novel-benzenesulfonamide-derivatives-as-larvicidal-and-antibacterial-agents-insi-35c10e7f4c527631PharmaRadar360en2026-09-27T00:00:00.000ZNovel benzenesulfonamide derivatives as larvicidal and antibacterial agents: insights from histopathological studies, molecular docking, and ADMET profilinghttps://www.pharmaradar360.com/article/mindful-eating-as-a-supportive-intervention-for-breast-cancer-survivors-a-pilot-6310ebfdeb068ec4PharmaRadar360en2026-09-27T00:00:00.000ZMindful eating as a supportive intervention for breast cancer survivors: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/hyperbaric-oxygen-therapy-as-an-adjunct-to-combined-oral-and-intratympanic-stero-2319ef287109c45fPharmaRadar360en2026-09-27T00:00:00.000ZHyperbaric Oxygen Therapy as an adjunct to Combined Oral and Intratympanic Steroids in Sudden Sensorineural Hearing Loss: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/molecular-identification-and-resistance-associated-gene-profiling-of-non-tubercu-a204bee6a51b8845PharmaRadar360en2026-09-27T00:00:00.000ZMolecular identification and resistance-associated gene profiling of non-tuberculous mycobacteria isolated from bovine clinical sampleshttps://www.pharmaradar360.com/article/clinical-features-in-children-with-loss-of-autism-diagnosis-and-persistent-autis-a8eb6187a65d377bPharmaRadar360en2026-09-27T00:00:00.000ZClinical Features in Children With Loss of Autism Diagnosis and Persistent Autism: A Comparative Studyhttps://www.pharmaradar360.com/article/nlrp3-inflammasome-inhibitors-as-precision-anti-inflammatory-pharmacotherapy-tra-21a39a95b16799d3PharmaRadar360en2026-09-27T00:00:00.000ZNLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challengeshttps://www.pharmaradar360.com/article/clinical-outcomes-during-concurrent-dupilumab-and-advanced-immune-modifying-ther-4ab55882ee92189bPharmaRadar360en2026-09-27T00:00:00.000ZClinical Outcomes During Concurrent Dupilumab and Advanced Immune-Modifying Therapy: A Real-World Cohort Studyhttps://www.pharmaradar360.com/article/the-prevalence-of-iga-nephropathy-in-japan-results-from-a-nationwide-survey-2ba8cf92e2c60190PharmaRadar360en2026-09-27T00:00:00.000ZThe prevalence of IgA nephropathy in Japan: results from a nationwide surveyhttps://www.pharmaradar360.com/article/association-between-abcg2-transporter-functionality-and-ckd-progression-a-retros-dc765de069efc1faPharmaRadar360en2026-09-27T00:00:00.000ZAssociation between ABCG2 transporter functionality and CKD progression: a retrospective cohort study in patients with CKD stage G3https://www.pharmaradar360.com/article/outcome-of-lumbar-fusion-with-template-guided-cortical-bone-trajectory-versus-tr-97ac0a6a9180565dPharmaRadar360en2026-09-27T00:00:00.000ZOutcome of lumbar fusion with template-guided cortical bone trajectory versus traditional pedicle screw trajectory – a prospective randomized trialhttps://www.pharmaradar360.com/article/combination-therapy-with-furosemide-and-metolazone-as-compared-to-furosemide-alo-de1fcda960bd54a1PharmaRadar360en2026-09-27T00:00:00.000ZCombination therapy with furosemide and metolazone as compared to furosemide alone for treatment of edema in children with nephrotic syndrome: a randomized controlled trialhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-adjuvant-sintilimab-monotherapy-in-high-risk-resected-eso-7e898f4d23ff8327PharmaRadar360en2026-09-27T00:00:00.000ZEfficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trialhttps://www.pharmaradar360.com/article/pressure-distribution-in-supine-postures-full-body-and-region-of-interest-analys-c6d302956be0d517PharmaRadar360en2026-09-27T00:00:00.000ZPressure Distribution in Supine Postures: Full-Body and Region of Interest Analysishttps://www.pharmaradar360.com/article/dino-by-paperbox-a-serious-gaming-platform-for-early-screening-of-learning-diffi-2194f2a855ef89a8PharmaRadar360en2026-09-27T00:00:00.000ZDINO by Paperbox: A Serious-Gaming Platform for Early Screening of Learning Difficulties in Childrenhttps://www.pharmaradar360.com/article/resting-hrv-signatures-of-psychological-burden-time-of-day-modulation-across-anx-d4ee4f19d5ea4d09PharmaRadar360en2026-09-27T00:00:00.000ZResting HRV Signatures of Psychological Burden: Time-of-Day Modulation across Anxiety, Stress, and Distresshttps://www.pharmaradar360.com/article/biomimetic-hyaluronic-acid-based-scaffolds-for-tissue-engineering-applications-b9a3e7220b0282e1PharmaRadar360en2026-09-27T00:00:00.000ZBiomimetic Hyaluronic Acid-Based Scaffolds for Tissue Engineering Applicationshttps://www.pharmaradar360.com/article/multifunctional-magnetofluorescent-carbon-dots-for-magnetic-hyperthermia-in-brea-8324b5a2c83f5066PharmaRadar360en2026-09-27T00:00:00.000ZMultifunctional Magnetofluorescent Carbon Dots for Magnetic Hyperthermia in Breast Cancer Modelshttps://www.pharmaradar360.com/article/pharmacoeconomic-analysis-of-noac-therapy-in-the-prevention-of-stroke-in-patient-937bb0adff7243a5PharmaRadar360en2026-09-27T00:00:00.000ZPharmacoeconomic Analysis of NOAC Therapy in the Prevention of Stroke in Patients with Atrial Fibrillationhttps://www.pharmaradar360.com/article/pillsguard-an-iot-based-system-for-safe-medication-administration-and-error-redu-b6c07865c3c77edfPharmaRadar360en2026-09-27T00:00:00.000ZPillsGuard: An IoT-Based System for Safe Medication Administration and Error Reduction in Clinical Environmentshttps://www.pharmaradar360.com/article/a-novel-iterative-image-reconstruction-method-for-low-dose-ct-based-on-artificia-5324af9f5c996f94PharmaRadar360en2026-09-27T00:00:00.000ZA Novel Iterative Image Reconstruction Method for Low-Dose CT based on Artificial Neural Networkshttps://www.pharmaradar360.com/article/microwave-medical-imaging-for-colorectal-cancer-detection-electromagnetic-simula-7a46a8758e5110cdPharmaRadar360en2026-09-27T00:00:00.000ZMicrowave Medical Imaging for Colorectal Cancer Detection: Electromagnetic Simulations and Tissue-Mimicking Material Fabricationhttps://www.pharmaradar360.com/article/a-patient-specific-flow-enabled-ultrasound-phantom-for-femoral-vascular-access-t-e393e485ff0d0af9PharmaRadar360en2026-09-27T00:00:00.000ZA Patient-Specific Flow-Enabled Ultrasound Phantom for Femoral Vascular Access Traininghttps://www.pharmaradar360.com/article/proof-of-concept-multilevel-linguistic-assessment-and-fmri-based-analysis-of-bra-e67de1c534849cf2PharmaRadar360en2026-09-27T00:00:00.000ZProof of Concept: Multilevel Linguistic Assessment and fMRI-Based Analysis of Brain Regions Involved in Language Learning in University-Level Studentshttps://www.pharmaradar360.com/article/feasibility-of-a-mixed-reality-framework-for-balance-assessment-in-multiple-scle-62482be7fcd59bf7PharmaRadar360en2026-09-27T00:00:00.000ZFeasibility of a Mixed Reality Framework for Balance Assessment in Multiple Sclerosishttps://www.pharmaradar360.com/article/from-users-to-co-creators-advancing-usability-in-medical-device-development-510c9555ffa129f3PharmaRadar360en2026-09-27T00:00:00.000ZFrom Users to Co‑Creators: Advancing Usability in Medical Device Developmenthttps://www.pharmaradar360.com/article/design-and-preliminary-testing-of-an-event-triggered-mixed-reality-system-for-at-6eebfa554bdf767ePharmaRadar360en2026-09-27T00:00:00.000ZDesign and Preliminary Testing of an Event-Triggered Mixed Reality System for Ataxia Assessmenthttps://www.pharmaradar360.com/article/quantitative-assessment-of-crossed-cerebellar-diaschisis-in-ischemic-stroke-usin-0aa19309d2652264PharmaRadar360en2026-09-27T00:00:00.000ZQuantitative Assessment of Crossed Cerebellar Diaschisis in Ischemic Stroke Using a CT Perfusion Normalization Frameworkhttps://www.pharmaradar360.com/article/static-and-motion-adaptive-temporal-propagation-for-vessel-segmentation-in-therm-d39bbee46391e36aPharmaRadar360en2026-09-27T00:00:00.000ZStatic and Motion-Adaptive Temporal Propagation for Vessel Segmentation in Thermal Infrared Videoshttps://www.pharmaradar360.com/article/detection-of-pressure-induced-faults-in-continuous-glucose-monitoring-sensors-us-ab623d40dd7413b3PharmaRadar360en2026-09-27T00:00:00.000ZDetection of Pressure-Induced Faults in Continuous Glucose Monitoring Sensors Using a Dynamic Time Warping-Based Approachhttps://www.pharmaradar360.com/article/sealed-rare-gas-system-for-cold-atmospheric-plasma-and-electromagnetic-energy-de-47adbde79d90ce85PharmaRadar360en2026-09-27T00:00:00.000ZSealed Rare-Gas System for Cold Atmospheric Plasma and Electromagnetic Energy Deliveryhttps://www.pharmaradar360.com/article/differentiating-cognitive-workload-requests-by-combined-behavioural-performance-5a634e7c81db0f63PharmaRadar360en2026-09-27T00:00:00.000ZDifferentiating Cognitive Workload Requests by Combined Behavioural Performance and HRV Metricshttps://www.pharmaradar360.com/article/data-driven-smart-clinical-engineering-a-multidimensional-assessment-of-patient-ba259059d9b88e7dPharmaRadar360en2026-09-27T00:00:00.000ZData-Driven Smart Clinical Engineering: A Multidimensional Assessment of Patient Safety, Operational Ethics, and ESG Sustainabilityhttps://www.pharmaradar360.com/article/additive-manufacturing-of-biocompatible-oculopalpebral-prostheses-a-workflow-for-d22293d0ede73b2bPharmaRadar360en2026-09-27T00:00:00.000ZAdditive Manufacturing of Biocompatible Oculopalpebral Prostheses: A Workflow for Personalized Design Approach to Reduce Clinical Timehttps://www.pharmaradar360.com/article/digital-training-platform-for-biomedical-equipment-management-412e27c0774d5ea1PharmaRadar360en2026-09-27T00:00:00.000ZDigital Training Platform for Biomedical Equipment Managementhttps://www.pharmaradar360.com/article/building-a-national-medical-equipment-inventory-in-greece-field-registration-pro-c85160ee567d0018PharmaRadar360en2026-09-27T00:00:00.000ZBuilding a National Medical Equipment Inventory in Greece: Field Registration Process and AI-Assisted Data Entry Across 129 Public Hospitalshttps://www.pharmaradar360.com/article/an-event-based-approach-to-estimate-motor-engagement-during-robot-assisted-gait-a8e565b6e7f874eaPharmaRadar360en2026-09-27T00:00:00.000ZAn Event-Based Approach to Estimate Motor Engagement During Robot-Assisted Gait Training Via Gaze-Related Featureshttps://www.pharmaradar360.com/article/a-practical-handheld-photoacoustic-microscopy-system-for-in-vivo-microvascular-i-0a3e005def802245PharmaRadar360en2026-09-27T00:00:00.000ZA Practical Handheld Photoacoustic Microscopy System for In Vivo Microvascular Imaginghttps://www.pharmaradar360.com/article/advancing-in-vivo-chimeric-antigen-receptor-t-cell-engineering-to-accelerate-cli-3fa8563db73df733PharmaRadar360en2026-09-27T00:00:00.000ZAdvancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translationhttps://www.pharmaradar360.com/article/what-are-the-benefits-and-harms-of-topical-cyclosporine-a-csa-0-05-for-people-wi-8d78566a5462f875PharmaRadar360en2026-09-27T00:00:00.000ZWhat are the benefits and harms of topical cyclosporine A (CsA) 0.05% for people with dry eye disease?https://www.pharmaradar360.com/article/for-adults-with-endometriosis-associated-pain-what-are-the-benefits-and-harms-of-68a72cbd94d48be1PharmaRadar360en2026-09-27T00:00:00.000ZFor adults with endometriosis-associated pain, what are the benefits and harms of daily oral progestogens compared with daily oral contraceptives?https://www.pharmaradar360.com/article/how-does-surgery-plus-systemic-treatment-compare-with-systemic-treatment-alone-f-ed3df23cb32b763aPharmaRadar360en2026-09-27T00:00:00.000ZHow does surgery plus systemic treatment compare with systemic treatment alone for women with metastatic breast cancer?https://www.pharmaradar360.com/article/araceli-biosciences-showcases-endeavor-imaging-system-at-mbc-biolabs-4c6a8304665c3dfcPharmaRadar360en2026-09-26T23:54:40.000ZAraceli Biosciences Showcases Endeavor Imaging System at MBC BioLabshttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-26T23:22:21.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-reveals-full-phase-2-trial-patient-data-for-ipf-drug-can-1b1d09e6ea1a1f01PharmaRadar360en2026-09-26T23:10:00.000ZDaewoong Pharmaceutical reveals full Phase 2 trial patient data for IPF drug candidate ‘Bersiporocin’ for the first timehttps://www.pharmaradar360.com/article/juniper-biosciences-receives-u-s-fda-breakthrough-therapy-designation-for-jbs-00-0da8c40634f4117cPharmaRadar360en2026-09-26T23:00:16.000ZJuniper Biosciences Receives U.S. FDA Breakthrough Therapy Designation for JBS-003 - MSKhttps://www.pharmaradar360.com/article/azetukalner-nda-submitted-ema-gives-approval-recommendation-to-ocrelizumab-phase-0f38194b2abaa2ddPharmaRadar360en2026-09-26T22:45:02.000ZAzetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points | NeurologyLive - Clinical Neurology News and Neurology Expert Insightshttps://www.pharmaradar360.com/article/food-safety-laws-exist-but-compliance-remains-a-challenge-maha-fda-af828665f42c5918PharmaRadar360en2026-09-26T22:31:27.000ZFood safety laws exist, but compliance remains a challenge: Maha FDAhttps://www.pharmaradar360.com/article/europe-injects-capital-into-colombian-biotech-firm-to-produce-250-million-vaccin-feb9a50256af0dcaPharmaRadar360en2026-09-26T22:31:00.000ZEurope Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccineshttps://www.pharmaradar360.com/article/grail-s-galleri-cancer-test-clears-fda-panel-on-safety-narrowly-backed-on-effect-a5d5ca427ce499d3PharmaRadar360en2026-09-26T22:17:39.000ZGRAIL's Galleri Cancer Test Clears FDA Panel On Safety, Narrowly Backed On Effectiveness: GRAL Stock In Focushttps://www.pharmaradar360.com/article/west-pharmaceutical-slides-as-glp-1-trade-cools-77e252e2e7686b78PharmaRadar360en2026-09-26T22:15:25.000ZWest Pharmaceutical Slides As GLP-1 Trade Coolshttps://www.pharmaradar360.com/article/amgen-stock-forecast-amgn-reclaims-410-as-pipeline-catalysts-build-7fbfcc7551885f60PharmaRadar360en2026-09-26T22:01:25.000ZAmgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Buildhttps://www.pharmaradar360.com/article/how-burning-rock-biotech-limited-bnr-affects-rotational-strategy-timing-f96bf4516451454fPharmaRadar360en2026-09-26T21:18:02.000ZHow Burning Rock Biotech Limited (BNR) Affects Rotational Strategy Timinghttps://www.pharmaradar360.com/article/waters-tops-growth-outlook-as-ai-demand-bd-integration-fuel-momentum-fd91aa9b29e1acd8PharmaRadar360en2026-09-26T21:02:03.000ZWaters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentumhttps://www.pharmaradar360.com/article/parkinson-drug-race-accelerates-as-lecun-sk-biopharm-roche-advance-chosunbiz-3ec3f140ea8d2dcfPharmaRadar360en2026-09-26T21:00:00.000ZParkinson drug race accelerates as LeCun, SK Biopharm, Roche advance - CHOSUNBIZhttps://www.pharmaradar360.com/article/no-2026-1269-public-health-warning-against-the-purchase-and-use-of-the-unregiste-2debac0e0a4f420fPharmaRadar360en2026-09-26T20:59:40.000ZNo.2026-1269 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Shira Yuki Beauty Is Power Ultimate Anti-aging and Whitening 180,000 mg i.m./i.v.” - Food and Drug Administrationhttps://www.pharmaradar360.com/article/nccn-journal-publishes-guidelines-update-in-mantle-cell-lymphoma-795f7701a8116285PharmaRadar360en2026-09-26T20:52:13.000ZNCCN Journal Publishes Guidelines Update in Mantle Cell Lymphomahttps://www.pharmaradar360.com/article/these-two-biotech-stocks-hit-fresh-52-week-highs-today-ntra-clocks-best-day-in-n-714beaedc7ee61b2PharmaRadar360en2026-09-26T20:51:19.000ZThese Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Monthshttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-adds-robert-plenge-to-its-board-4edf4740359ab614PharmaRadar360en2026-09-26T20:42:30.000ZBioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Boardhttps://www.pharmaradar360.com/article/sylvia-ortega-martinez-appointed-cdmo-scouting-business-development-director-ame-8e1509594a9436a8PharmaRadar360en2026-09-26T20:29:10.000ZSylvia Ortega Martinez Appointed CDMO Scouting & Business Development Director, Americas at EUROAPIhttps://www.pharmaradar360.com/article/solara-tightens-kyc-norms-for-physical-shareholders-under-sebi-mandate-73d7255028bee488PharmaRadar360en2026-09-26T19:26:04.000ZSolara Tightens KYC Norms for Physical Shareholders Under SEBI Mandatehttps://www.pharmaradar360.com/article/imvax-glioblastoma-data-backs-move-toward-phase-3-trial-955e35904ca54980PharmaRadar360en2026-09-26T19:12:29.000ZImvax Glioblastoma Data Backs Move Toward Phase 3 Trialhttps://www.pharmaradar360.com/article/salvador-carlucci-appointed-chief-executive-officer-at-avizum-ai-0869f7c60b4c3ac5PharmaRadar360en2026-09-26T18:57:31.000ZSalvador Carlucci Appointed Chief Executive Officer at AVIZUM.AIhttps://www.pharmaradar360.com/article/vktx-stock-lags-glp-1-peers-in-july-but-viking-ceo-says-its-obesity-drug-could-o-55e28e0768872cf0PharmaRadar360en2026-09-26T17:40:53.000ZVKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’thttps://www.pharmaradar360.com/article/post-mi-heart-failure-prevention-intracoronary-mesenchymal-stem-cell-phase-3-tri-cfd907156a7043cePharmaRadar360en2026-09-26T17:18:43.000ZPost-MI heart failure prevention: intracoronary mesenchymal stem cell phase 3 trial retractedhttps://www.pharmaradar360.com/article/dbt-ils-bioincubator-hosts-startup-career-fair-bringing-17-ventures-together-in-4c4084fb98df1ba4PharmaRadar360en2026-09-26T17:08:47.000ZDBT-ILS Bioincubator Hosts Startup Career Fair, Bringing 17 Ventures Together in Bhubaneswarhttps://www.pharmaradar360.com/article/top-biotech-stocks-to-add-to-your-watchlist-september-26th-8ef2ab914c9a2348PharmaRadar360en2026-09-26T17:08:24.000ZTop Biotech Stocks To Add to Your Watchlist - September 26thhttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-secures-shareholder-approval-for-shareholder-categ-94f0a8f68750daa8PharmaRadar360en2026-09-26T16:56:10.000ZSun Pharmaceutical Industries secures shareholder approval for shareholder category reclassificationhttps://www.pharmaradar360.com/article/navigating-biopharma-complexity-why-long-term-partnerships-matter-39b1115d3c1f4806PharmaRadar360en2026-09-26T16:46:52.000ZNavigating Biopharma Complexity: Why Long-Term Partnerships Matterhttps://www.pharmaradar360.com/article/50-pro-life-leaders-ask-fda-to-restore-abortion-pill-safeguards-3c8a9605a983c3f5PharmaRadar360en2026-09-26T16:00:00.000Z50 pro-life leaders ask FDA to restore abortion pill safeguardshttps://www.pharmaradar360.com/article/kerala-to-overhaul-kmscl-medicine-procurement-new-tenders-from-oct-substandard-d-e6f09e5fd85e2d1aPharmaRadar360en2026-09-26T15:58:26.000ZKerala to overhaul KMSCL medicine procurement; new tenders from Oct, substandard drug suppliers to be blacklistedhttps://www.pharmaradar360.com/article/influence-carries-responsibility-maha-fda-backs-prez-murmu-s-message-to-film-sta-42308c55eae682a8PharmaRadar360en2026-09-26T15:33:41.000Z‘Influence Carries Responsibility’: Maha FDA Backs Prez Murmu’s Message To Film Starshttps://www.pharmaradar360.com/article/rare-diseases-when-patients-drive-the-pharmaceutical-industry-forward-11bc97e6b3da333aPharmaRadar360en2026-09-26T15:23:38.000ZRare diseases: when patients drive the pharmaceutical industry forwardhttps://www.pharmaradar360.com/article/drug-chain-needs-more-checks-not-fewer-links-say-pharmacists-5fd312141c985abePharmaRadar360en2026-09-26T15:21:00.000ZDrug chain needs more checks, not fewer links, say pharmacistshttps://www.pharmaradar360.com/article/aarti-drugs-shares-strategic-growth-plans-at-41st-annual-general-meeting-403fdd2404c5095dPharmaRadar360en2026-09-26T14:58:35.000ZAarti Drugs shares strategic growth plans at 41st Annual General Meetinghttps://www.pharmaradar360.com/article/mundhe-says-food-safety-regulations-are-there-non-compliance-is-biggest-issue-2388734a4081e7dePharmaRadar360en2026-09-26T14:29:14.000ZMundhe says food safety regulations are there, non-compliance is biggest issuehttps://www.pharmaradar360.com/article/nigeria-strengthens-pharmaceutical-sector-059cc79d0a191956PharmaRadar360en2026-09-26T14:28:43.000ZNigeria Strengthens Pharmaceutical Sectorhttps://www.pharmaradar360.com/article/9th-annual-dart-to-the-finish-charity-walk-set-for-saturday-oct-3-at-tod-s-point-81a0b58709f75524PharmaRadar360en2026-09-26T14:20:06.000Z9th Annual DART to the Finish Charity Walk Set for Saturday, Oct 3 at Tod’s Pointhttps://www.pharmaradar360.com/article/tozorakimab-reduces-copd-exacerbations-in-phase-3-trials-7f83549668471ce8PharmaRadar360en2026-09-26T14:07:14.000ZTozorakimab Reduces COPD Exacerbations in Phase 3 Trialshttps://www.pharmaradar360.com/article/amylyx-pharmaceuticals-inc-amlx-stock-price-news-quote-history-789e68f08611ad33PharmaRadar360en2026-09-26T14:04:28.000ZAmylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & Historyhttps://www.pharmaradar360.com/article/the-fda-just-rushed-out-emergency-treatments-against-a-parasite-that-can-reach-h-8ca0b03aaf8b0074PharmaRadar360en2026-09-26T14:00:00.000ZThe FDA Just Rushed Out Emergency Treatments Against a Parasite That Can Reach Humanshttps://www.pharmaradar360.com/article/people-don-t-realise-how-food-safety-lapses-risk-public-health-mundhe-96d9e156af20511dPharmaRadar360en2026-09-26T13:56:55.000ZPeople don't realise how food safety lapses risk public health: Mundhehttps://www.pharmaradar360.com/article/biohaven-ltd-bhvn-stock-price-news-quote-and-history-fb88cd800d8486a4PharmaRadar360en2026-09-26T13:43:20.000ZBiohaven Ltd. (BHVN) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/fg-plans-wider-role-for-pharmacists-in-nigeria-s-healthcare-system-2ad038d37b1e7ddbPharmaRadar360en2026-09-26T13:30:00.000ZFG Plans Wider Role For Pharmacists In Nigeria’s Healthcare System -https://www.pharmaradar360.com/article/total-equity-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-r-00f908fabf9044daPharmaRadar360en2026-09-26T13:19:57.000ZTotal equity of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/russia-attacks-darnytsia-pharmaceutical-plant-for-second-time-in-a-week-cb5106cc9d0ca398PharmaRadar360en2026-09-26T13:02:00.000ZRussia attacks Darnytsia pharmaceutical plant for second time in a weekhttps://www.pharmaradar360.com/article/tame-the-aging-trial-with-metformin-that-never-enrolled-a-patient-6e5dadaf0968b86dPharmaRadar360en2026-09-26T12:29:30.000ZTAME: The Aging Trial with Metformin That Never Enrolled a Patienthttps://www.pharmaradar360.com/article/darnytsia-pharmaceutical-company-hit-by-aggressor-for-second-time-over-week-a029e621c0dc5c54PharmaRadar360en2026-09-26T12:29:19.000ZDarnytsia pharmaceutical company hit by aggressor for second time over weekhttps://www.pharmaradar360.com/article/astellas-doses-first-patient-in-phase-3-trial-of-setidegrasib-for-kras-g12d-muta-c428c99ab0d4452fPharmaRadar360en2026-09-26T12:13:02.000ZAstellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancerhttps://www.pharmaradar360.com/article/will-priority-review-change-takeda-stock-s-narrative-fcb5f6d65b62f1d7PharmaRadar360en2026-09-26T11:50:00.000ZWill Priority Review Change Takeda Stock's Narrativehttps://www.pharmaradar360.com/article/is-sellas-life-sciences-group-sls-fully-priced-as-sls009-data-draws-attention-33c46e2f002a8753PharmaRadar360en2026-09-26T11:26:00.000ZIs SELLAS Life Sciences Group (SLS) Fully Priced As SLS009 Data Draws Attention?https://www.pharmaradar360.com/article/pharmaceutical-keynote-speaker-for-events-scott-steinberg-2114dc5da09c0841PharmaRadar360en2026-09-26T11:25:47.000ZPharmaceutical Keynote Speaker for Events | Scott Steinberghttps://www.pharmaradar360.com/article/preity-zinta-s-team-tukaram-mundhe-t-shirt-receives-a-response-from-the-fda-comm-64781058aebeee2fPharmaRadar360en2026-09-26T11:01:00.000ZPreity Zinta’s ‘Team Tukaram Mundhe’ T-shirt receives a response from the FDA Commissioner himself. ‘Havenhttps://www.pharmaradar360.com/article/opinion-why-do-clinical-trials-for-cancer-drugs-take-so-long-5af8d4c7ae806337PharmaRadar360en2026-09-26T11:00:08.000ZOpinion | Why Do Clinical Trials for Cancer Drugs Take So Long?https://www.pharmaradar360.com/article/ai-drug-discovery-on-the-eve-of-full-value-realization-in-modern-pharmaceutical-06757b6282d027abPharmaRadar360en2026-09-26T10:52:25.000ZAI Drug Discovery: On the Eve of Full Value Realization in Modern Pharmaceutical Innovationhttps://www.pharmaradar360.com/article/clinical-data-harmonization-is-the-bottleneck-for-life-sciences-ai-6523456644754b15PharmaRadar360en2026-09-26T10:37:04.000ZClinical data harmonization is the bottleneck for life sciences AIhttps://www.pharmaradar360.com/article/commentary-the-prescription-drug-affordability-board-is-working-it-s-time-to-pre-c716bb20e31d28e8PharmaRadar360en2026-09-26T10:18:42.000ZCommentary: The Prescription Drug Affordability Board is working, it's time to press forward, not backhttps://www.pharmaradar360.com/article/results-are-due-monday-from-a-study-of-two-potential-treatments-for-an-age-relat-87cd3e491349b862PharmaRadar360en2026-09-26T10:05:31.000ZResults are due Monday from a study of two potential treatments for an age-related eye disease.https://www.pharmaradar360.com/article/what-s-next-in-ataxia-pipeline-overview-of-investigational-therapeutics-84047120bac91bc5PharmaRadar360en2026-09-26T10:02:37.000ZWhat's Next in Ataxia: Pipeline Overview of Investigational Therapeuticshttps://www.pharmaradar360.com/article/the-drug-industry-s-care-gap-novo-aims-to-diversify-and-more-94fb54d839beca63PharmaRadar360en2026-09-26T10:00:00.000ZThe drug industry’s care gap; Novo aims to diversify; and morehttps://www.pharmaradar360.com/article/daratumumab-pomalidomide-maintenance-after-salvage-autologous-transplantation-in-c3e01295f5bae9d3PharmaRadar360en2026-09-26T09:34:29.000ZDaratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study | Blood Cancer Journalhttps://www.pharmaradar360.com/article/russia-hits-kyiv-pharmaceutical-plant-second-time-in-a-week-f81a10d67ee2ab91PharmaRadar360en2026-09-26T09:31:06.000ZRussia Hits Kyiv Pharmaceutical Plant Second Time in a Weekhttps://www.pharmaradar360.com/article/us-thalidomide-survivors-push-for-federal-recognition-and-compensation-c0a598d4b846436dPharmaRadar360en2026-09-26T09:00:00.000ZUS thalidomide survivors push for federal recognition and compensationhttps://www.pharmaradar360.com/article/russian-forces-strike-darnytsia-pharmaceutical-plant-in-kyiv-again-14945dbed4fb36a5PharmaRadar360en2026-09-26T08:58:00.000ZRussian forces strike Darnytsia pharmaceutical plant in Kyiv againhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-nasdaq-rare-stock-has-consensus-price-target-of-34-cc9516ac59c30051PharmaRadar360en2026-09-26T08:34:28.000ZUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analystshttps://www.pharmaradar360.com/article/fda-approves-baricitinib-for-severe-alopecia-areata-in-adolescents-12-b0565e53ceb12441PharmaRadar360en2026-09-26T07:28:44.000ZFDA approves baricitinib for severe alopecia areata in adolescents 12+https://www.pharmaradar360.com/article/eli-002-7p-phase-2-data-selected-for-esmo-2026-oral-presentation-51bca2865302a680PharmaRadar360en2026-09-26T06:43:43.000ZELI-002 7P Phase 2 Data Selected for ESMO 2026 Oral Presentationhttps://www.pharmaradar360.com/article/russia-struck-the-pharmaceutical-company-darnitsa-for-the-second-time-in-four-da-e1a4757d3eb9349fPharmaRadar360en2026-09-26T06:32:53.000ZRussia struck the pharmaceutical company "Darnitsa" for the second time in four dayshttps://www.pharmaradar360.com/article/simply-wearing-a-t-shirt-is-not-enough-fda-chief-tukaram-mundhes-reacts-to-preit-39989874a8f5d9a0PharmaRadar360en2026-09-26T06:05:59.000ZSimply Wearing A T-Shirt Is Not Enough: FDA Chief Tukaram Mundhes REACTS To Preity Zintas Viral Teamhttps://www.pharmaradar360.com/article/total-assets-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-r-0ebd88a86d57b92bPharmaRadar360en2026-09-26T05:34:13.000ZTotal assets of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/fda-launches-inspection-at-kmf-dairies-across-22-districts-afa99d2d8639ec2aPharmaRadar360en2026-09-26T05:27:08.000ZFDA launches inspection at KMF dairies across 22 districtshttps://www.pharmaradar360.com/article/pancreatic-cancer-emerging-breakthroughs-and-clinical-strategies-686d4bc8668cb3c4PharmaRadar360en2026-09-26T04:16:57.000ZPancreatic Cancer: Emerging Breakthroughs and Clinical Strategieshttps://www.pharmaradar360.com/article/greenland-mines-nasdaq-grml-sets-q4-biotech-spin-off-as-company-sharpens-critica-827b8cea89bf7fccPharmaRadar360en2026-09-26T03:52:02.000ZGreenland Mines (NASDAQ: GRML) Sets Q4 Biotech Spin-Off as Company Sharpens Critical Minerals Focushttps://www.pharmaradar360.com/article/total-liabilities-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-in-2ba17615a74ef7daPharmaRadar360en2026-09-26T03:12:20.000ZTotal liabilities of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/acadia-pharmaceuticals-announces-phase-3-enabling-topline-results-from-phase-2-r-bfc2d18115b8e3c4PharmaRadar360en2026-09-26T02:45:00.000ZAcadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)https://www.pharmaradar360.com/article/burning-rock-biotech-ltd-bnr-shares-surge-3-3-what-gf-scor-5e0b4dd39ed88219PharmaRadar360en2026-09-26T02:35:46.000ZBurning Rock Biotech Ltd (BNR) Shares Surge 3.3% -- What GF Scorhttps://www.pharmaradar360.com/article/maia-biotechnology-files-resale-prospectus-for-751-879-shares-994c1b7db293f72aPharmaRadar360en2026-09-26T02:30:37.000ZMAIA Biotechnology files resale prospectus for 751,879 shareshttps://www.pharmaradar360.com/article/fda-accepts-teva-s-ecopipam-nda-for-pediatric-tourette-syndrome-c5eb1b0babcb189fPharmaRadar360en2026-09-26T02:15:38.000ZFDA accepts Teva's ecopipam NDA for pediatric Tourette syndromehttps://www.pharmaradar360.com/article/fda-ema-meeting-opens-botanical-drugs-conversation-7c94c8f0804d5178PharmaRadar360en2026-09-26T02:07:05.000ZFDA/EMA meeting opens botanical drugs conversationhttps://www.pharmaradar360.com/article/anti-abortion-group-gives-fda-60-days-to-act-on-mifepristone-or-face-endangered-f5683c942acc8e6fPharmaRadar360en2026-09-26T02:00:46.000ZAnti-Abortion Group Gives FDA 60 Days to Act on Mifepristone or Face Endangered Species Act Lawsuithttps://www.pharmaradar360.com/article/consumers-lose-another-damages-lawsuit-against-allergan-over-breast-implants-lin-7a6c784d7492eabcPharmaRadar360en2026-09-26T01:53:41.000ZConsumers Lose Another Damages Lawsuit Against Allergan Over Breast Implants Linked to Cancer Riskhttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524PharmaRadar360en2026-09-26T01:53:15.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/ai-natural-medicine-biotech-enveda-raises-311m-series-e-9ab31ef431554506PharmaRadar360en2026-09-26T01:50:01.000ZAI Natural-Medicine Biotech Enveda Raises $311M Series Ehttps://www.pharmaradar360.com/article/radiation-oncology-s-biggest-meeting-returns-to-boston-with-landmark-trials-in-b-3471382a6296c1e5PharmaRadar360en2026-09-26T01:33:45.000ZRadiation Oncology’s Biggest Meeting Returns to Boston With Landmark Trials in Breast, Liver and Lung Cancerhttps://www.pharmaradar360.com/article/ag-fitch-urges-nsc-to-protect-glp-1-drugs-cda4d5edfcdcd63cPharmaRadar360en2026-09-26T01:05:16.000ZAG Fitch urges NSC to protect GLP-1 Drugshttps://www.pharmaradar360.com/article/how-chinese-biotech-is-graduating-from-licensing-deals-to-broader-partnerships-183cd687d9726f33PharmaRadar360en2026-09-26T01:00:08.000ZHow Chinese biotech is graduating from licensing deals to broader partnershipshttps://www.pharmaradar360.com/article/us-fda-approves-mirum-s-drug-for-rare-bone-disorder-f4845fdf4afd5840PharmaRadar360en2026-09-26T00:45:42.000ZUS FDA approves Mirum’s drug for rare bone disorderhttps://www.pharmaradar360.com/article/new-biotech-startup-at-stanford-is-run-by-thousands-of-ai-agents-475453ac2c308eefPharmaRadar360en2026-09-26T00:43:04.000ZNew biotech startup at Stanford is run by thousands of AI agentshttps://www.pharmaradar360.com/article/food-biotech-is-moving-behind-the-label-0f6be4fba0036f13PharmaRadar360en2026-09-26T00:41:07.000ZFood Biotech Is Moving Behind the Labelhttps://www.pharmaradar360.com/article/total-debt-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-4e3da3a19b763c2aPharmaRadar360en2026-09-26T00:21:58.000ZTotal debt of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-and-2-japanese-ai-healthcare-stocks-to-own-dad20d1ebc13d0efPharmaRadar360en2026-09-26T00:13:00.000ZChugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Ownhttps://www.pharmaradar360.com/article/evaluating-the-clinical-use-of-cefoperazone-sulbactam-and-post-discharge-antibio-de43bf2af77c554dPharmaRadar360en2026-09-26T00:00:00.000ZEvaluating the Clinical Use of Cefoperazone/ Sulbactam and Post-discharge Antibiotics Practices in Infectious Diseases Patientshttps://www.pharmaradar360.com/article/polycystic-ovary-syndrome-pcos-associated-infertility-clinical-insights-and-emer-83c6bc6c8507db43PharmaRadar360en2026-09-26T00:00:00.000ZPolycystic Ovary Syndrome (PCOS) -Associated Infertility: Clinical Insights and Emerging Deep Learning Approaches for Early Detection and Predictionhttps://www.pharmaradar360.com/article/low-dose-silodosin-for-premature-ejaculation-a-clinical-evaluation-45c0c2795e660c9fPharmaRadar360en2026-09-26T00:00:00.000ZLow-Dose Silodosin for Premature Ejaculation: A Clinical Evaluationhttps://www.pharmaradar360.com/article/sociodemographic-and-clinical-characteristics-of-tuberculosispositivity-and-rifa-4ce74de0c5bbbec3PharmaRadar360en2026-09-26T00:00:00.000ZSociodemographic and Clinical Characteristics of TuberculosisPositivity and Rifampicin Resistance among Presumptive Patients inSouthern Punjab, Pakistan: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/african-hla-diversity-and-its-implications-for-transfusion-transplantation-infec-97b857cf9a314545PharmaRadar360en2026-09-26T00:00:00.000ZAfrican HLA Diversity and Its Implications for Transfusion, Transplantation, Infectious-Disease Immunity, Vaccination and Pharmacogenomicshttps://www.pharmaradar360.com/article/harnessing-coordinated-cd4-and-cd8-t-cell-immunity-for-virus-specific-adoptive-i-1b602c6ec922594cPharmaRadar360en2026-09-26T00:00:00.000ZHarnessing Coordinated CD4⁺ and CD8⁺ T-Cell Immunity for Virus-Specific Adoptive Immunotherapy in Africahttps://www.pharmaradar360.com/article/induced-pluripotent-stem-cell-derived-chimeric-antigen-receptor-natural-killer-c-d1be5f82d021a8a7PharmaRadar360en2026-09-26T00:00:00.000ZInduced pluripotent stem cell-derived chimeric antigen receptor natural killer cells: Engineering innovations, translational hurdles and clinical prospects in immune therapyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-oral-paracetamol-versus-intravenous-paracetamol-in-preter-1aeadb35921e3545PharmaRadar360en2026-09-26T00:00:00.000ZEfficacy and safety of oral paracetamol versus intravenous paracetamol in preterm infants with patent ductus arteriosus: a randomised controlled trialhttps://www.pharmaradar360.com/article/p4ha3-promotes-gastric-cancer-cell-proliferation-and-invasion-via-the-pi3k-akt-m-33a6b1c82ca3a9d0PharmaRadar360en2026-09-26T00:00:00.000ZP4HA3 promotes gastric cancer cell proliferation and invasion via the PI3K/AKT/mTOR signaling pathway and regulates glycolytic metabolic reprogramminghttps://www.pharmaradar360.com/article/comparative-evaluation-of-medication-adherence-and-health-related-quality-of-lif-ee8db90c935c5ed5PharmaRadar360en2026-09-26T00:00:00.000ZComparative Evaluation of Medication Adherence and Health-Related Quality of Life with SGLT-2 Versus DPP-4 Inhibitors in Type 2 Diabetes Mellitus: A 12-Month Prospective Observational Studyhttps://www.pharmaradar360.com/article/terapia-hormonal-de-la-menopausia-reevaluacion-del-balance-riesgo-beneficio-dos-dd70098654c62292PharmaRadar360en2026-09-26T00:00:00.000ZTERAPIA HORMONAL DE LA MENOPAUSIA: REEVALUACIÓN DEL BALANCE RIESGO-BENEFICIO DOS DÉCADAS DESPUÉS DEL ESTUDIO WOMEN'S HEALTH INITIATIVE (WHI)https://www.pharmaradar360.com/article/digital-twin-of-drug-induced-liver-injury-and-systemic-adverse-drug-reactions-in-0551ae2a8f18f7f0PharmaRadar360en2026-09-26T00:00:00.000ZDIGITAL TWIN OF DRUG-INDUCED LIVER INJURY AND SYSTEMIC ADVERSE DRUG REACTIONS IN MASS MEDICATION SCENARIOS: PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELShttps://www.pharmaradar360.com/article/the-intersection-of-artificial-intelligence-and-intellectual-property-the-impact-66b51a1456a6de5bPharmaRadar360en2026-09-26T00:00:00.000ZThe Intersection of Artificial Intelligence and Intellectual Property: The Impact of Data Exclusivity Policies on Pharmaceutical Production in Africahttps://www.pharmaradar360.com/article/iron-accumulation-in-non-transfusion-dependent-thalassemia-from-molecular-mechan-d1c333f0838c0072PharmaRadar360en2026-09-26T00:00:00.000ZIron accumulation in non-transfusion-dependent thalassemia: From molecular mechanisms to clinical practicehttps://www.pharmaradar360.com/article/effects-of-sauna-and-waon-therapy-on-cardiovascular-function-and-clinical-outcom-2d7175966a24da73PharmaRadar360en2026-09-26T00:00:00.000ZEffects of Sauna and Waon Therapy on Cardiovascular Function and Clinical Outcomes in Patients with Chronic Heart Failure or Coronary Artery Disease: Systematic Reviewhttps://www.pharmaradar360.com/article/a-case-of-atypical-occult-hepatitis-b-infection-obi-with-hbsag-negativity-and-hi-d4a1743a51e55130PharmaRadar360en2026-09-26T00:00:00.000ZA case of Atypical Occult Hepatitis B Infection (OBI) with HBsAg Negativity and High Anti-HBs Titer: Clinical implicationshttps://www.pharmaradar360.com/article/effect-of-multi-modal-training-in-patients-with-mild-cognitive-impairment-a-rand-423debf0992ec711PharmaRadar360en2026-09-26T00:00:00.000ZEffect of Multi-Modal Training in Patients With Mild Cognitive Impairment: A Randomized Controlled Pilot Trialhttps://www.pharmaradar360.com/article/sex-differences-in-sentiment-scored-vocabulary-patterns-in-vaers-free-text-narra-3d06f6c8aa9c3a7bPharmaRadar360en2026-09-26T00:00:00.000ZSex Differences in Sentiment-Scored Vocabulary Patterns in VAERS Free-Text Narratives of Four Major Vaccine Categorieshttps://www.pharmaradar360.com/article/enhancing-skin-penetration-of-a-hydrophilic-large-molecular-weight-compound-usin-f56a6a4d8e2bb9a3PharmaRadar360en2026-09-26T00:00:00.000ZEnhancing Skin Penetration of a Hydrophilic, Large Molecular Weight Compound Using a Nanoparticle-in-Oil Dispersionhttps://www.pharmaradar360.com/article/comparison-of-salivary-cortisol-cortisone-and-dexamethasone-with-serum-measureme-d76f10631ca18dd3PharmaRadar360en2026-09-26T00:00:00.000ZComparison of Salivary Cortisol, Cortisone, and Dexamethasone with Serum Measurements Across Dynamic Adrenal Testinghttps://www.pharmaradar360.com/article/fluid-intolerance-signals-as-bedside-safety-limits-during-early-septic-shock-res-f4a9bdb767151ed4PharmaRadar360en2026-09-26T00:00:00.000ZFluid-intolerance signals as bedside safety limits during early septic shock resuscitation: a multicenter randomized trialhttps://www.pharmaradar360.com/article/when-the-system-fails-the-community-leads-field-insights-from-the-self-efficacy-93ebbf8aed800074PharmaRadar360en2026-09-26T00:00:00.000ZWhen the system fails, the community leads: field insights from the self-efficacy and knowledge (SEEK) trial during Lebanon’s 2024 active conflicthttps://www.pharmaradar360.com/article/clinical-biochemical-and-genetic-spectra-of-carnosinemia-a-systematic-review-of-e2c70be37f41686ePharmaRadar360en2026-09-26T00:00:00.000ZClinical, biochemical and genetic spectra of carnosinemia: a systematic review of case reports and case serieshttps://www.pharmaradar360.com/article/postprandial-lipopolysaccharide-after-a-saturated-compared-to-monounsaturated-fa-d14b5d2d6417c0fbPharmaRadar360en2026-09-26T00:00:00.000ZPostprandial lipopolysaccharide after a saturated compared to monounsaturated fatty acid enriched high fat meal in older adults: a randomized control trialhttps://www.pharmaradar360.com/article/when-nudges-are-not-enough-an-ethics-of-escalating-behavioural-interventions-in-93e891b830e4c076PharmaRadar360en2026-09-26T00:00:00.000ZWhen nudges are not enough: an ethics of escalating behavioural interventions in clinical decision-makinghttps://www.pharmaradar360.com/article/perceptions-of-micro-learning-modules-on-knowledge-retention-and-clinical-decisi-0a8cffb9f2848e80PharmaRadar360en2026-09-26T00:00:00.000ZPerceptions of micro-learning modules on knowledge retention and clinical decision-making among physiotherapists: a cross-sectional studyhttps://www.pharmaradar360.com/article/platinum-based-chemotherapy-and-nephrotoxicity-frequency-clinical-characteristic-d4cca52e1258bb58PharmaRadar360en2026-09-26T00:00:00.000ZPlatinum-based chemotherapy and nephrotoxicity: frequency, clinical characteristics and outcomes in a mexican tertiary-centre cohorthttps://www.pharmaradar360.com/article/machine-learning-models-combining-multimodal-ultrasound-and-clinical-factors-for-0587d6eee90880e1PharmaRadar360en2026-09-26T00:00:00.000ZMachine learning models combining multimodal ultrasound and clinical factors for predicting ischemic stroke risk in patients with carotid plaqueshttps://www.pharmaradar360.com/article/idiopathic-granulomatous-inflammation-of-the-periocular-structures-in-four-dogs-8d673f367bc771fePharmaRadar360en2026-09-26T00:00:00.000ZIdiopathic Granulomatous Inflammation of the Periocular Structures in Four Dogs: Clinical, Histopathological, and Imaging Findings and Therapeutic Outcomehttps://www.pharmaradar360.com/article/preparation-and-i-in-vitro-i-evaluation-of-amphotericin-b-chondroitin-sulfate-po-67ac2740a793f501PharmaRadar360en2026-09-26T00:00:00.000ZPreparation and <i>in vitro</i> evaluation of amphotericin B-chondroitin sulfate polymer prodrughttps://www.pharmaradar360.com/article/effects-of-virtual-reality-based-aerobic-exercise-versus-traditional-aerobic-exe-0726fa7784af4fbdPharmaRadar360en2026-09-26T00:00:00.000ZEffects of virtual reality-based aerobic exercise versus traditional aerobic exercise training on physical fitness, functional capacity, and quality of life in individuals with Down syndrome: DOWNFIT (Down Syndrome Fitness Intervention Trial) randomized controlled trialhttps://www.pharmaradar360.com/article/clinician-curated-chatgpt-4o-and-deepseek-r1-assisted-exercise-programmes-added-1854cdd7da17f8a5PharmaRadar360en2026-09-26T00:00:00.000ZClinician-curated ChatGPT-4o– and DeepSeek-R1–assisted exercise programmes added to standard physiotherapy for subacromial pain syndrome: a triple-masked randomized controlled trialhttps://www.pharmaradar360.com/article/benchmarking-model-based-design-of-experiment-approaches-with-a-pharmaceutical-c-39b3209501f13f07PharmaRadar360en2026-09-26T00:00:00.000ZBenchmarking model-based design of experiment approaches with a pharmaceutical crystallisation emulatorhttps://www.pharmaradar360.com/article/semaglutide-and-tirzepatide-in-cardiovascular-and-cardiometabolic-risk-managemen-3a1c317d994a2f39PharmaRadar360en2026-09-26T00:00:00.000ZSemaglutide and Tirzepatide in Cardiovascular and Cardiometabolic Risk Management: Evidence Maturity, Patient Selection, and Real-World Implementationhttps://www.pharmaradar360.com/article/relationship-between-breast-arterial-calcification-detected-on-mammography-and-c-b61df578ae71bdd2PharmaRadar360en2026-09-26T00:00:00.000ZRelationship Between Breast Arterial Calcification Detected on Mammography and Carotid Intima Media Thickness as a Marker for Subclinical Atherosclerosishttps://www.pharmaradar360.com/article/health-literacy-primary-healthcare-accessibility-and-hypertension-self-care-mana-161c74695fc7a346PharmaRadar360en2026-09-26T00:00:00.000ZHealth Literacy, Primary Healthcare Accessibility and Hypertension Self-Care Management Among Adults in an Urban Slum of New Delhi: A Community-Based Cross-Sectional Studyhttps://www.pharmaradar360.com/article/clinicians-perspectives-on-the-design-of-multi-output-ai-based-early-warning-sys-96c5ad937ea54cfdPharmaRadar360en2026-09-26T00:00:00.000ZClinicians’ Perspectives on the Design of Multi-Output AI-Based Early Warning Systems for Clinical Deterioration: A Qualitative Analysishttps://www.pharmaradar360.com/article/association-of-the-5-item-modified-frailty-index-and-chronological-age-with-post-cbf14f8eb36fce46PharmaRadar360en2026-09-26T00:00:00.000ZAssociation of the 5-item modified frailty index and chronological age with postoperative length of stay after CRS–HIPEC: a single-centre cohort studyhttps://www.pharmaradar360.com/article/internalized-weight-stigma-and-associated-clinical-features-in-treatment-seeking-83ea0ad14fda1f23PharmaRadar360en2026-09-26T00:00:00.000ZInternalized weight stigma and associated clinical features in treatment-seeking adults with obesity: a multicenter Italian studyhttps://www.pharmaradar360.com/article/automated-reporting-for-serum-immunofixation-electrophoresis-using-a-two-stage-d-43c8f7d90ebbeb81PharmaRadar360en2026-09-26T00:00:00.000ZAutomated Reporting for Serum Immunofixation Electrophoresis Using a Two-Stage Decision-Support Systemhttps://www.pharmaradar360.com/article/blockchain-based-pharmaceutical-supply-chain-a-scalable-and-transparent-model-fo-7c8d96259f0a09b5PharmaRadar360en2026-09-26T00:00:00.000ZBlockchain-based pharmaceutical supply chain: a scalable and transparent model for drug traceabilityhttps://www.pharmaradar360.com/article/development-and-clinical-translation-of-a-stepwise-simulation-based-curriculum-f-f94eb722ad3070c8PharmaRadar360en2026-09-26T00:00:00.000ZDevelopment and clinical translation of a stepwise simulation-based curriculum for robotic lung transplantationhttps://www.pharmaradar360.com/article/design-of-thermoresponsive-pnipam-coated-hollow-bimetallic-nanocomposites-for-ph-7d6337f875827942PharmaRadar360en2026-09-26T00:00:00.000ZDesign of thermoresponsive PNIPAM-coated hollow bimetallic nanocomposites for photothermal-enhanced drug delivery and chemo-photothermal therapyhttps://www.pharmaradar360.com/article/beyond-kpaq-improvement-reassessing-the-clinical-meaning-of-cilostazol-rosuvasta-6a232b0f64ce470dPharmaRadar360en2026-09-26T00:00:00.000ZBeyond KPAQ Improvement: Reassessing the Clinical Meaning of Cilostazol–Rosuvastatin Combination Therapy in Symptomatic Peripheral Artery Diseasehttps://www.pharmaradar360.com/article/splice-site-variants-in-neurology-from-molecular-mechanisms-to-clinical-interpre-47616a2bbc486454PharmaRadar360en2026-09-26T00:00:00.000ZSplice-site variants in neurology: from molecular mechanisms to clinical interpretation — a focused reviewhttps://www.pharmaradar360.com/article/dietary-inflammatory-potential-and-oral-periodontal-health-in-children-a-cross-s-c6073d301f8193afPharmaRadar360en2026-09-26T00:00:00.000ZDietary inflammatory potential and oral–periodontal health in children: a cross-sectional study based on the children’s dietary inflammatory index dietary inflammatory potential and oral-periodontal health in childrenhttps://www.pharmaradar360.com/article/effect-of-surface-treatment-protocols-and-thermocycling-on-the-optical-surface-a-c467701c4ba52a3bPharmaRadar360en2026-09-26T00:00:00.000ZEffect of surface treatment protocols and thermocycling on the optical, surface, and mechanical properties of additively manufactured resin materialshttps://www.pharmaradar360.com/article/influence-of-cold-plasma-activation-on-fluoride-uptake-and-demineralization-of-e-eb9109194738a3a2PharmaRadar360en2026-09-26T00:00:00.000ZInfluence of cold plasma activation on fluoride uptake and demineralization of enamelhttps://www.pharmaradar360.com/article/association-of-cannabis-use-disorder-with-clinical-outcomes-following-lumbar-spi-856f9a813f88bb67PharmaRadar360en2026-09-26T00:00:00.000ZAssociation of cannabis use disorder with clinical outcomes following lumbar spinal fusion: a propensity-matched cohort studyhttps://www.pharmaradar360.com/article/nanoliposomal-silymarin-as-a-multi-mechanistic-therapy-for-nafld-dose-dependent-cc068a3b9bcdbfcbPharmaRadar360en2026-09-26T00:00:00.000ZNanoliposomal silymarin as a multi-mechanistic therapy for NAFLD: dose-dependent amelioration of hepatic steatosis, fibrosis, and oxidative stress in a rat modelhttps://www.pharmaradar360.com/article/low-handgrip-strength-in-advanced-cancer-associated-factors-and-clinical-implica-7269a0855ff7e4c1PharmaRadar360en2026-09-26T00:00:00.000ZLow handgrip strength in advanced cancer: associated factors and clinical implications in palliative carehttps://www.pharmaradar360.com/article/novel-semi-automated-system-for-multi-dimensional-analysis-of-macular-neovascula-7bebf046e75cd0e0PharmaRadar360en2026-09-26T00:00:00.000ZNovel semi-automated system for multi-dimensional analysis of macular neovascularization: quantitative biomarkers and rule-based morphological categorization across OCTA platformshttps://www.pharmaradar360.com/article/impact-of-covid-19-on-refractive-amblyopia-risk-factors-in-5-years-old-children-b5d42cfabe22f6ffPharmaRadar360en2026-09-26T00:00:00.000ZImpact of COVID-19 on refractive amblyopia risk factors in 5-years-old children: A nationwide cross sectional studyhttps://www.pharmaradar360.com/article/the-spiz-study-rationale-and-protocol-of-a-randomized-controlled-trial-to-optimi-ba23ab4a9346904bPharmaRadar360en2026-09-26T00:00:00.000ZThe SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care modelhttps://www.pharmaradar360.com/article/clinical-and-laboratory-characteristics-distinguishing-node-first-kawasaki-disea-4e3f1b106d63d0ffPharmaRadar360en2026-09-26T00:00:00.000ZClinical and Laboratory Characteristics Distinguishing Node-First Kawasaki Disease from Bacterial Cervical Lymphadenitis: A Systematic Reviewhttps://www.pharmaradar360.com/article/pharmaceutical-innovation-in-advanced-nanomedicine-for-the-treatment-of-hypervir-18f8abae5a555e61PharmaRadar360en2026-09-26T00:00:00.000ZPharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infectionshttps://www.pharmaradar360.com/article/child-human-in-the-loop-ood-detection-for-safe-clinical-deployment-63f5fa2dc79454b0PharmaRadar360en2026-09-26T00:00:00.000ZCHILD: Human-in-the-Loop OOD Detection for Safe Clinical Deploymenthttps://www.pharmaradar360.com/article/biogait-vlm-a-tri-modal-vision-language-biomechanics-framework-for-interpretable-1233b179f74e6545PharmaRadar360en2026-09-26T00:00:00.000ZBioGait-VLM: A Tri-Modal Vision–Language–Biomechanics Framework for Interpretable Clinical Gait Assessmenthttps://www.pharmaradar360.com/article/atomimed-hierarchical-atomic-fact-checking-for-universal-clinical-aware-medical-3d7e99bd2b99d254PharmaRadar360en2026-09-26T00:00:00.000ZAtomiMed: Hierarchical Atomic Fact-Checking for Universal Clinical-Aware Medical Report Evaluationhttps://www.pharmaradar360.com/article/biomass-derived-carbon-dots-based-frap-analog-for-sensitive-evaluation-of-antiox-7fc4c245e4935099PharmaRadar360en2026-09-26T00:00:00.000ZBiomass‐Derived Carbon Dots–Based FRAP Analog for Sensitive Evaluation of Antioxidant Activity: Application to Pharmaceutical Products and Plant Extractshttps://www.pharmaradar360.com/article/radiation-oncology-advances-take-center-stage-as-md-anderson-presents-nearly-70-87e51b03e2b16e48PharmaRadar360en2026-09-25T23:47:44.000ZRadiation Oncology Advances Take Center Stage as MD Anderson Presents Nearly 70 Abstracts at ASTRO 2026https://www.pharmaradar360.com/article/edsa-stock-rallied-over-50-today-what-s-ahead-for-the-small-cap-biotech-ad8c8a2cd49d9062PharmaRadar360en2026-09-25T23:26:34.000ZEDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?https://www.pharmaradar360.com/article/murkowski-concerned-fda-pick-may-limit-chemical-abortion-killing-of-preborn-alas-a423c9902e1ff283PharmaRadar360en2026-09-25T23:16:57.000ZMurkowski ‘concerned’ FDA pick may limit chemical abortion killing of preborn Alaskanshttps://www.pharmaradar360.com/article/mirum-pharmaceuticals-and-incyte-announce-u-s-fda-approval-of-atebrioztm-zilurgi-96934ff33681f0d8PharmaRadar360en2026-09-25T23:00:00.000ZMirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressivahttps://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-xbi-stock-price-news-quote-and-history-c439df664c2384a2PharmaRadar360en2026-09-25T22:54:20.000ZState Street SPDR S&P Biotech ETF (XBI) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/budd-blunt-rochester-introduce-bill-to-establish-biometrology-laboratory-program-35bcca7365f58ae5PharmaRadar360en2026-09-25T22:47:49.000ZBudd, Blunt Rochester Introduce Bill to Establish Biometrology Laboratory Program, Accelerate Development in Biotechhttps://www.pharmaradar360.com/article/jusvinza-demonstrates-efficacy-against-chikungunya-12a3a0f4e6296e42PharmaRadar360en2026-09-25T22:28:26.000ZJusvinza demonstrates efficacy against chikungunyahttps://www.pharmaradar360.com/article/zeria-pharmaceutical-co-ltd-tse-4559-looks-like-a-good-stock-and-it-s-going-ex-d-6fb6c2f2205f1cfbPharmaRadar360en2026-09-25T22:07:10.000ZZeria Pharmaceutical Co., Ltd. (TSE:4559) Looks Like A Good Stock, And It's Going Ex-Dividend Soonhttps://www.pharmaradar360.com/article/consideration-of-the-political-declaration-on-pandemic-prevention-preparedness-a-a6e8e4bc3b7ddcd2PharmaRadar360en2026-09-25T22:00:28.000ZConsideration of the Political Declaration on Pandemic Prevention, Preparedness, and Response (PPPR)https://www.pharmaradar360.com/article/fda-confirmation-hearing-gives-update-on-abortion-pill-study-under-new-leadershi-25744d59fca613e4PharmaRadar360en2026-09-25T22:00:00.000ZFDA Confirmation Hearing Gives Update on Abortion Pill Study Under New Leadershiphttps://www.pharmaradar360.com/article/community-pharmacist-prescribing-service-planned-for-october-2026-start-20a197d64ffbf786PharmaRadar360en2026-09-25T21:41:15.000ZCommunity pharmacist prescribing service planned for October 2026 starthttps://www.pharmaradar360.com/article/pharmacy-at-the-heart-of-welsh-government-s-healthcare-priorities-3e55daddcdec949fPharmaRadar360en2026-09-25T21:41:15.000ZPharmacy ‘at the heart’ of Welsh government’s healthcare prioritieshttps://www.pharmaradar360.com/article/supporting-patients-who-are-clinically-vulnerable-to-covid-19-330ca89993016f45PharmaRadar360en2026-09-25T21:41:15.000ZSupporting patients who are clinically vulnerable to COVID-19https://www.pharmaradar360.com/article/claude-spots-a-mystery-enzyme-scientists-overlooked-b519ab51c3d3b672PharmaRadar360en2026-09-25T21:36:05.000ZClaude spots a mystery enzyme scientists overlookedhttps://www.pharmaradar360.com/article/fda-commissioner-nominee-affirms-mmr-vaccine-safety-despite-trump-s-claims-e1569d4826e14760PharmaRadar360en2026-09-25T21:31:56.000ZFDA commissioner nominee affirms MMR vaccine safety despite Trump’s claimshttps://www.pharmaradar360.com/article/here-s-how-much-1000-invested-in-krystal-biotech-5-years-ago-would-be-worth-toda-33624fb55441f011PharmaRadar360en2026-09-25T21:30:24.000ZHere's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Todayhttps://www.pharmaradar360.com/article/krystal-biotech-krys-stock-looks-stretched-against-current-earnings-power-41a3057190af1eb4PharmaRadar360en2026-09-25T21:27:48.000ZKrystal Biotech (KRYS) Stock Looks Stretched Against Current Earnings Powerhttps://www.pharmaradar360.com/article/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026-154208859fc4f121PharmaRadar360en2026-09-25T21:15:00.000ZVeracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026